MPA (Medroxyprogesterone acetate)

Catalog No.S2567 Batch:S256706

Print

Technical Data

Formula

C24H34O4
Molecular Weight 386.52 CAS No. 71-58-9
Solubility (25°C)* In vitro DMSO 18 mg/mL (46.56 mM)
Ethanol 15 mg/mL (38.8 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 30%PEG300 5%Tween80 60%ddH2O
0.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 600 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MPA (Medroxyprogesterone acetate) is a synthetic progestin and act as a potent progesterone receptor agonist, used to treat abnormal menstruation or irregular vaginal bleeding.
Targets
progestogen Receptor [1]
In vitro

Medroxyprogesterone acetate (MPA) inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone (DHP) and 3alpha, 5alpha-tetrahydroprogesterone (THP), and therefore may affect the local actions of DHP and THP in the brain. [1]

Medroxyprogesterone acetate (MPA) reduces secretion of IL-6 and PTHrP from human breast cancer cells. MPA dose-dependently decreases the secretion and mRNA expression of IL-6 and PTHrP in the KTC-2 cells. [2]

Medroxyprogesterone acetate (MPA) and dexamethasone dose dependently increases alpha-ENaC promoter-driven luciferase activity in M-1 cells, which is not inhibited by Org31710, indicating that Medroxyprogesterone acetate regulates alpha-ENaC in a PR-independent manner. Medroxyprogesterone acetate and dexamethasone, but not progesterone, dose dependently increases alpha-ENaC and sgk1 mRNA in M-1 and in Madin-Darby canine kidney-C7 cells, both collecting duct cell lines. [3]

Medroxyprogesterone acetate (MPA) (0.1 nM) significantly enhances the in vitro production of specific immunoglobulin G (IgG) antibodies, an effect that appears to involve the interaction of the progestin with PRG receptors[4]
In vivo

Medroxyprogesterone acetate (MPA) impairs delayed memory retention on the water radial-arm maze (WRAM), and exacerbates overnight forgetting on the Morris maze (MM) in aged ovariectomized (OVX) rats. Medroxyprogesterone acetate (MPA) significantly and progesterone marginally decreases GAD levels in the hippocampus, and both MPA and progesterone significantly increases GAD levels in the entorhinal cortex. [5]

Protocol (from reference)

Cell Assay:

[6]
  • Cell lines

    ISK cells

  • Concentrations

    29.3 µM

  • Incubation Time

    48 h

  • Method

    Cells were treated with various concentrations of drug for 48 h.
Animal Study:

[1]
  • Animal Models

    Wistar albino female rats

  • Dosages

    1, 2, 4, or 8 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , Molecular Pain, 2015, 11:46.]

Selleck's MPA (Medroxyprogesterone acetate) has been cited by 12 publications

The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death [ Cancer Rep (Hoboken), 2024, 7(1):e1934] PubMed: 38013666
Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy [ Br J Cancer, 2023, 129(4):601-611] PubMed: 37402867
Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy [ Br J Cancer, 2023, 129(4):601-611] PubMed: 37402867
Elevated high-mannose N-glycans hamper endometrial decidualization [ iScience, 2023, 10.1016/j.isci.2023.108170] PubMed: 37915610
RNA-seq and ATAC-seq analysis of CD163+ macrophage-induced progestin-insensitive endometrial cancer cells [ Cancer Med, 2023, 12(5):5964-5978] PubMed: 36373483
ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL [ Cell Death Dis, 2022, 13(12):1067] PubMed: 36550099
Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB [ Front Oncol, 2021, 11:665832] PubMed: 33937078
Characteristics of Circular RNA Expression in Ishikawa Human Endometrial Carcinoma Cells with Progesterone Treatment [ Research Square, 2020, 10.21203/rs.3.rs-30247/v1] PubMed: None
poFUT1 promotes endometrial decidualization by enhancing the O-fucosylation of Notch1 [ EBioMedicine, 2019, 44:563-573] PubMed: 31201143
poFUT1 promotes uterine angiogenesis and vascular remodeling via enhancing the O-fucosylation on uPA [ Cell Death Dis, 2019, 10(10):775] PubMed: 31601791

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.